The Retrogenix platform has been used to advance therapeutic developments for COVID-19, such as: identifying potential human plasma membrane therapeutic targets for viral cell entry, and safety screening COVID-19 biotherapeutics.
Identification of such receptors, and safety screening COVID-19 therapies, will help to progress therapeutic developments.
How can our cell microarray platform advance therapeutic development for COVID-19?
Retrogenix’s unique cell microarray technology provides a fast, accurate solution for discovering the human cell surface and secreted protein targets of antibodies, proteins, CAR-T cells, viruses, and small molecules.
Our unique tool uses proprietary arrays of expression vectors – encoding over 6,200 human plasma membrane, tethered secreted, and heterodimer proteins – spotted onto slides. Human cells grown over the top become reverse-transfected, resulting in cell surface expression of each respective protein at distinct slide locations. The test molecule is applied and specific binding analysed and confirmed using an appropriate detection system.
Jo Soden, Co-founder and Director at Retrogenix, says:
“By screening against our unique library of human cell surface proteins, Retrogenix has previously been highly successful in identifying viral receptors. Using the same technology, we now have the perfect opportunity to search for new receptors for COVID-19.
A positive find could have significant consequences in the search for treatments.”
See below to find out how to stay up to date with this research.